{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T04:27:02Z","timestamp":1771302422670,"version":"3.50.1"},"reference-count":96,"publisher":"Siapec Servizi Srl","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-164","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T13:39:00Z","timestamp":1611754740000},"page":"138-152","source":"Crossref","is-referenced-by-count":8,"title":["Neoplastic and pre-neoplastic lesions of the oesophagus and gastro-oesophageal junction"],"prefix":"10.32074","volume":"112","author":[{"given":"Federica","family":"Grillo","sequence":"first","affiliation":[]},{"given":"Luca","family":"Mastracci","sequence":"additional","affiliation":[]},{"given":"Luca","family":"Saragoni","sequence":"additional","affiliation":[]},{"given":"Alessandro","family":"Vanoli","sequence":"additional","affiliation":[]},{"given":"Francesco","family":"Limarzi","sequence":"additional","affiliation":[]},{"given":"Irene","family":"Gullo","sequence":"additional","affiliation":[]},{"given":"Jacopo","family":"Ferro","sequence":"additional","affiliation":[]},{"given":"Michele","family":"Paudice","sequence":"additional","affiliation":[]},{"given":"Paola","family":"Parente","sequence":"additional","affiliation":[]},{"given":"Matteo","family":"Fassan","sequence":"additional","affiliation":[]}],"member":"21774","published-online":{"date-parts":[[2020,9]]},"reference":[{"key":"10.32074\/1591-951X-164_ref1","unstructured":"WHO Classification of Tumours of the Digestive System. 5th ed. Geneva: World Health Organization Classification of Tumours. WHO Classification of Tumours Editorial Board. Lyon: IARC press 2019."},{"key":"10.32074\/1591-951X-164_ref2","unstructured":"RARECARENet Information Network on Rare Cancers. Accessed: 15 Sept 2019. Available from http:\/\/rarecarenet.eu\/index.php"},{"key":"10.32074\/1591-951X-164_ref3","doi-asserted-by":"crossref","unstructured":"Pan Q-J, Roth MJ, Guo H-Q, et al. Cytologic detection of esophageal squamous cell carcinoma and its precursor lesions using balloon samplers and liquid-based cytologyin asymptomatic adults in Llinxian, China. Acta Cytol 2008;52:14-23. https:\/\/doi.org\/10.1159\/000325430","DOI":"10.1159\/000325430"},{"key":"10.32074\/1591-951X-164_ref4","doi-asserted-by":"crossref","unstructured":"Ismail-Beigi F, Horton PF, Pope CE. Histological consequences of gastroesophageal reflux in man. Gastroenterol 1970;58:163-74.","DOI":"10.1016\/S0016-5085(70)80004-X"},{"key":"10.32074\/1591-951X-164_ref5","doi-asserted-by":"crossref","unstructured":"Weinstein WM, Bogoch ER, Bowes KL. The normal human esophageal mucosa : a histological rappraisal. Gastroenterol 1975;68:40-4.","DOI":"10.1016\/S0016-5085(75)80046-1"},{"key":"10.32074\/1591-951X-164_ref6","doi-asserted-by":"crossref","unstructured":"Taylor PR, Abnet CC, Dawsey SM. Squamous dysplasia-the precursor lesion for esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2013;22:540-52. https:\/\/doi.org\/10.1158\/1055-9965.EPI-12-1347","DOI":"10.1158\/1055-9965.EPI-12-1347"},{"key":"10.32074\/1591-951X-164_ref7","doi-asserted-by":"crossref","unstructured":"Dawsey SM, Lewin KJ, Liu FS, et al. Esophageal morphology from Linxian, China. Squamous histologic findings in 754 patients. Cancer 1994;73:2027-37. https:\/\/doi.org\/10.1002\/1097-0142(19940415)73:8<2027::aid-cncr2820730803> 3.0.co;2-3","DOI":"10.1002\/1097-0142(19940415)73:8<2027::AID-CNCR2820730803>3.0.CO;2-3"},{"key":"10.32074\/1591-951X-164_ref8","doi-asserted-by":"crossref","unstructured":"Wang LD, Yanh HH, Fan ZM, et al. Cytological screening and 15 years\u2019 follow-up (1986-2001) for early esophageal squamous cell carcinoma and precancerous lesions in a high-risk population in Anyang Country, Henan Province, Northern China. Cancer Detect Prev 2005;29:317-22. https:\/\/doi.org\/10.1016\/j.cdp.2005.06.004","DOI":"10.1016\/j.cdp.2005.06.004"},{"key":"10.32074\/1591-951X-164_ref9","doi-asserted-by":"crossref","unstructured":"Savant D, Zhang Q, Yang Z. Squamous Neoplasia in the Esophagus. Arch Pathol Lab Med 2020. Epub ahead of print. https:\/\/doi.org\/10.5858\/arpa.2020-0058-RA","DOI":"10.5858\/arpa.2020-0058-RA"},{"key":"10.32074\/1591-951X-164_ref10","doi-asserted-by":"crossref","unstructured":"Arista-Nasr J, Rivera I, Martinez-Benitez B, et al. Atypical regenerative hyperplasia of the esophagus in endoscopy biopsy: a mimicker of squamous esophageal carcinoma. Arch Pathol Lab Med 2005;129:899-904. https:\/\/doi.org\/10.1043\/1543-2165(2005)129[899:ARHOTE]2.0.CO;2","DOI":"10.5858\/2005-129-899-ARHOTE"},{"key":"10.32074\/1591-951X-164_ref11","doi-asserted-by":"crossref","unstructured":"Shimizu M, Ban S, Odze RD. Squamous dysplasia and other precursor lesions related to esophageal squamous cell carcinoma. Gastroenterol Clin N Am 2007;36:797-811. https:\/\/doi.org\/10.1016\/j.gtc.2007.08.005","DOI":"10.1016\/j.gtc.2007.08.005"},{"key":"10.32074\/1591-951X-164_ref12","doi-asserted-by":"crossref","unstructured":"Soga J, Tanaka O, Sasaki K, et al. Superficial spreading carcinoma of the esophagus. Cancer 1982;50:1641-5. https:\/\/doi.org\/10.1002\/1097-0142(19821015)50:8<1641::aid-cncr2820500830> 3.0.co;2-9","DOI":"10.1002\/1097-0142(19821015)50:8<1641::AID-CNCR2820500830>3.0.CO;2-9"},{"key":"10.32074\/1591-951X-164_ref13","doi-asserted-by":"crossref","unstructured":"Biemond P, ten Kate FJ, Van Blankenstein M. Esophageal verrucous carcinoma: histologically a low-grade malignancy but clinically a fatal disease. J Clin Gastroenterol 1991;13:102-7.","DOI":"10.1097\/00004836-199102000-00023"},{"key":"10.32074\/1591-951X-164_ref14","doi-asserted-by":"crossref","unstructured":"Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med 2014;371:2499-2509. https:\/\/doi.org\/10.1056\/NEJMra1314530","DOI":"10.1056\/NEJMra1314530"},{"key":"10.32074\/1591-951X-164_ref15","doi-asserted-by":"crossref","unstructured":"Rossini AR, Hashimoto CL, Iriya K, et al. Dietary habits, ethanol and tobacco consumption as predictive factors in the development of esophageal carcinoma in patients with head and neck neoplasms. Dis Esophagus 2008;21:316-21. https:\/\/doi.org\/10.1111\/j.1442-2050.2007.00769.x","DOI":"10.1111\/j.1442-2050.2007.00769.x"},{"key":"10.32074\/1591-951X-164_ref16","doi-asserted-by":"crossref","unstructured":"Saftoiu A, Hassan C, Areia M., et al. Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europe : European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2020;52:293-304. https:\/\/doi.org\/10.1055\/a-1104-5245","DOI":"10.1055\/a-1104-5245"},{"key":"10.32074\/1591-951X-164_ref17","doi-asserted-by":"crossref","unstructured":"Muto M, Hironaka S, Nakane M., et al. Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. Gastrointest Endosc 2002;56:517-21. https:\/\/doi.org\/10.1067\/mge.2002.128104","DOI":"10.1067\/mge.2002.128104"},{"key":"10.32074\/1591-951X-164_ref18","doi-asserted-by":"crossref","unstructured":"Zendehedel K, Nyr\u00e8n O, Edberg A, et al. Risk of esophageal adenocarcinoma in achalasia patients, a retrospective cohort study in Sweden. Am J Gastroenterol 2011;106:57-61. https:\/\/doi.org\/10.1038\/ajg.2010.449","DOI":"10.1038\/ajg.2010.449"},{"key":"10.32074\/1591-951X-164_ref19","doi-asserted-by":"crossref","unstructured":"Blaydon DC, Etheridge SL, Risk JM, et al. RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am J Hum Genet 2012;90:340-6. https:\/\/doi.org\/10.1016\/j.ajhg.2011.12.008","DOI":"10.1016\/j.ajhg.2011.12.008"},{"key":"10.32074\/1591-951X-164_ref20","doi-asserted-by":"crossref","unstructured":"Ravi K, Geno DM, Katzka DA. Esophageal cancer screening in achalasia: is there a consensus? Dis Esophagus 2015;28:299-304. https:\/\/doi.org\/10.1111\/dote.12196","DOI":"10.1111\/dote.12196"},{"key":"10.32074\/1591-951X-164_ref21","doi-asserted-by":"crossref","unstructured":"Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, et al. The Global Burden of Cancer 2013. Jama Oncol 2015;1:505-27. https:\/\/doi.org\/10.1001\/jamaoncol.2015.0735","DOI":"10.1001\/jamaoncol.2015.0735"},{"key":"10.32074\/1591-951X-164_ref22","doi-asserted-by":"crossref","unstructured":"Xie SH, Lagergen J. A global assessment of the male predominance in esophageal adenocarcinoma. Oncotarget 2016;7:38876-83. https:\/\/doi.org\/10.18632\/oncotarget.9113","DOI":"10.18632\/oncotarget.9113"},{"key":"10.32074\/1591-951X-164_ref23","doi-asserted-by":"crossref","unstructured":"Qu X, Ben Q, Jiang Y. Consumption of red and processed meat and risk for esophageal squamous cell carcinoma based on a meta-analysis. Ann Epidemiol 2013;23:762-70. https:\/\/doi.org\/10.1016\/j.annepidem.2013.09.003","DOI":"10.1016\/j.annepidem.2013.09.003"},{"key":"10.32074\/1591-951X-164_ref24","doi-asserted-by":"crossref","unstructured":"Chen Y, Tong Y, Yang C, et al. Consumption of hot beverages and foods and the risk of esophageal cancer: a meta-analysis of observational studies. BMC Cancer 2015;15:449. https:\/\/doi.org\/10.1186\/s12885-015-1185-1","DOI":"10.1186\/s12885-015-1185-1"},{"key":"10.32074\/1591-951X-164_ref25","doi-asserted-by":"crossref","unstructured":"Wu C, Wang Z, Song X, et al. Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. Nat Genet 2014;46:1001-6. https:\/\/doi.org\/10.1038\/ng.3064","DOI":"10.1158\/1538-7445.AM2014-2204"},{"key":"10.32074\/1591-951X-164_ref26","doi-asserted-by":"crossref","unstructured":"Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v50-7. https:\/\/doi.org\/10.1093\/annonc\/mdw329","DOI":"10.1093\/annonc\/mdw329"},{"key":"10.32074\/1591-951X-164_ref27","doi-asserted-by":"crossref","unstructured":"Van Hagen P, Hulshof MC, Van Lanschot JJ, et al. Preoperative chemioradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84. https:\/\/doi.org\/10.1056\/NEJMoa1112088","DOI":"10.1056\/NEJMoa1112088"},{"key":"10.32074\/1591-951X-164_ref28","doi-asserted-by":"crossref","unstructured":"Shapiro J, Van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090-8. https:\/\/doi.org\/10.1016\/S1470-2045(15)00040-6","DOI":"10.1016\/S1470-2045(15)00040-6"},{"key":"10.32074\/1591-951X-164_ref29","doi-asserted-by":"crossref","unstructured":"Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 11th Edition: part I. Esophagus 2017;14:37-65. https:\/\/doi.org\/10.1007\/s10388-016-0556-2","DOI":"10.1007\/s10388-016-0556-2"},{"key":"10.32074\/1591-951X-164_ref30","doi-asserted-by":"crossref","unstructured":"Osborn NK, Keate RF, Trastek VF, et al. Verrucous carcinoma of the esophagus: clinicopathophysiologic features and treatment of a rare entity. Dig Dis Sci 2003;48: 465-74. https:\/\/doi.org\/10.1023\/a:1022572229285","DOI":"10.1023\/A:1022572229285"},{"key":"10.32074\/1591-951X-164_ref31","doi-asserted-by":"crossref","unstructured":"Al-Shoha M, Nadeem U, George N, et al. Verrucous carcinoma of the esophagus-remains a diagnostic enigma. Am J Gastroenterol 2018;113:919-21. https:\/\/doi.org\/10.1038\/s41395-018-0065-0","DOI":"10.1038\/s41395-018-0065-0"},{"key":"10.32074\/1591-951X-164_ref32","doi-asserted-by":"crossref","unstructured":"Tripathi M, Swanson PE. Rare tumors of esophageal squamous mucosa. Ann N Y Acad Sci 2016;1381:122-32. https:\/\/doi.org\/10.1111\/nyas.13108","DOI":"10.1111\/nyas.13108"},{"key":"10.32074\/1591-951X-164_ref33","unstructured":"Lyomasa S, Kato H, Tachimori Y, et al. Carcinosarcoma of the esophagus: a twenty-case study. Jpn Clin Oncol 1990;20:99-106."},{"key":"10.32074\/1591-951X-164_ref34","doi-asserted-by":"crossref","unstructured":"Raza MA, Mazzara PF. Sarcomatoid carcinoma of esophagus. Arch Pathol Lab Med 2011;135:945-8. https:\/\/doi.org\/10.1043\/2010-0074-RSR.1","DOI":"10.5858\/2010-0074-RSR.1"},{"key":"10.32074\/1591-951X-164_ref35","doi-asserted-by":"crossref","unstructured":"Bellizzi AM, Woodford RL, Moskauk CA, et al. Basaloid squamous cell carcinoma of the esophagus: assessment of high-risk human papillomavirusand realted molecular markers. Am J Surg Pathol 2009;33:1608-14. https:\/\/doi.org\/10.1097\/PAS.0b013e3181b46fd4","DOI":"10.1097\/PAS.0b013e3181b46fd4"},{"key":"10.32074\/1591-951X-164_ref36","doi-asserted-by":"crossref","unstructured":"Lin DC, Wang MR, Koeffler HP. Genomic and epigenomic aberrations in esophageal squamous cell carcinoma and implications for patients. Gastroenterology 2018;154:374-89. https:\/\/doi.org\/10.1053\/j.gastro.2017.06.066","DOI":"10.1053\/j.gastro.2017.06.066"},{"key":"10.32074\/1591-951X-164_ref37","doi-asserted-by":"crossref","unstructured":"Walker RC, Underwood TJ. Molecular pathways in the development and treatment of oesophageal cancer. Best Pract Res Clin Gastroenterol 2018;36-37:9-15. doi 10.1016\/j.bpg.2018.11.013","DOI":"10.1016\/j.bpg.2018.11.013"},{"key":"10.32074\/1591-951X-164_ref38","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517:576-82. https:\/\/doi.org\/10.1038\/nature14129","DOI":"10.1038\/nature14129"},{"key":"10.32074\/1591-951X-164_ref39","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25. https:\/\/doi.org\/10.1038\/nature11404","DOI":"10.1038\/nature11404"},{"key":"10.32074\/1591-951X-164_ref40","doi-asserted-by":"crossref","unstructured":"Odze RD. Diagnosis and grading of dysplasia in Barrett\u2019s oesophagus. J Clin Pathol 2006;59:1029-38. https:\/\/doi.org\/10.1136\/jcp.2005.035337","DOI":"10.1136\/jcp.2005.035337"},{"key":"10.32074\/1591-951X-164_ref41","doi-asserted-by":"crossref","unstructured":"Voltaggio L, Montgomery EA, Lam-Himlin D. A clinical and histopathologic focus on Barrett esophagus and Barrett-related dysplasia. Arch Pathol Lab Med 2011;135:1249-60. https:\/\/doi.org\/10.5858\/arpa.2011-0019-RA","DOI":"10.5858\/arpa.2011-0019-RA"},{"key":"10.32074\/1591-951X-164_ref42","doi-asserted-by":"crossref","unstructured":"Lomo LC, Blount PL, Sanchez CA, et al. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett\u2019s esophagus cohort. Am J Surg Pathol 2006;30:423-35. https:\/\/doi.org\/10.1097\/00000478-200604000-00001","DOI":"10.1097\/00000478-200604000-00001"},{"key":"10.32074\/1591-951X-164_ref43","doi-asserted-by":"crossref","unstructured":"Coco DP, Goldblum JR, Hornick JL, et al. Interobserver variability in the diagnosis of crypt dysplasia in Barret Esophagus. Am J Surg Pathol 2011;35:45-54. https:\/\/doi.org\/10.1097\/PAS.0b013e3181ffdd14","DOI":"10.1097\/PAS.0b013e3181ffdd14"},{"key":"10.32074\/1591-951X-164_ref44","doi-asserted-by":"crossref","unstructured":"Rugge M, Correa P, Dixon MF, et al. Gastric Dysplasia. The Padova International Classification. Am J Surg Pathol 2000;24:167-76. https:\/\/doi.org\/10.1097\/00000478-200002000-00001","DOI":"10.1097\/00000478-200002000-00001"},{"key":"10.32074\/1591-951X-164_ref45","doi-asserted-by":"crossref","unstructured":"Anaparthy R, Sharma P. Progression of Barrett oesophagus: role of endoscopic and histological predictors. Nat Rev Gastroenterol Hepatol 2014;11:525-34. https:\/\/doi.org\/10.1038\/nrgastro.2014.69","DOI":"10.1038\/nrgastro.2014.69"},{"key":"10.32074\/1591-951X-164_ref46","doi-asserted-by":"crossref","unstructured":"Hardikar S, Onstad L, Blount PL, et al. The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett\u2019s esophagus. PLoS ONE 2013;8:e52192. https:\/\/doi.org\/10.1371\/journal.pone.0052192","DOI":"10.1371\/journal.pone.0052192"},{"key":"10.32074\/1591-951X-164_ref47","doi-asserted-by":"crossref","unstructured":"Corley DA, Kubo A, Levin TR, et al. Race, ethnicity, sex and temporal differences in Barrett\u2019s oesophagus diagnosis: a large community-based study, 1994-2006. Gut 2009;58:182-8. https:\/\/doi.org\/10.1136\/gut.2008.163360","DOI":"10.1136\/gut.2008.163360"},{"key":"10.32074\/1591-951X-164_ref48","doi-asserted-by":"crossref","unstructured":"Anaparthy R, Gaddam S, Kanakadandi V, et al. Association between length of Barrett\u2019s esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol 2013;11:1430-6. https:\/\/doi.org\/10.1016\/j.cgh.2013.05.007","DOI":"10.1016\/j.cgh.2013.05.007"},{"key":"10.32074\/1591-951X-164_ref49","doi-asserted-by":"crossref","unstructured":"Parasa S, Venalaganti S, Gaddam S, et al, Development and validation of a model to determine risk of progression of Barret\u2019s Esophagus to Neoplasia. Gastroenterology 2018;154:1282-9. https:\/\/doi.org\/10.1053\/j.gastro.2017.12.009","DOI":"10.1053\/j.gastro.2017.12.009"},{"key":"10.32074\/1591-951X-164_ref50","doi-asserted-by":"crossref","unstructured":"Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett\u2019s oesophagus: a meta-analysis. Gut 2012;61:970-6. https:\/\/doi.org\/10.1136\/gutjnl-2011-300730","DOI":"10.1136\/gutjnl-2011-300730"},{"key":"10.32074\/1591-951X-164_ref51","doi-asserted-by":"crossref","unstructured":"Singh S, Manickam P, Amin AV, et al. Incidence of esophageal adenocarcinoma in Barrett\u2019s esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc 2014;79:897-909. https:\/\/doi.org\/10.1016\/j.gie.2014.01.009","DOI":"10.1016\/j.gie.2014.01.009"},{"key":"10.32074\/1591-951X-164_ref52","doi-asserted-by":"crossref","unstructured":"Rastogi A, Puli S, El-Serag HB, et al. Incidence of esophageal adenocarcinoma in patients with Barrett\u2019s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 2008;67:394-8. https:\/\/doi.org\/10.1016\/j.gie.2007.07.019","DOI":"10.1016\/j.gie.2007.07.019"},{"key":"10.32074\/1591-951X-164_ref53","doi-asserted-by":"crossref","unstructured":"Curvers WL, Ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett\u2019s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523-30. https:\/\/doi.org\/10.1038\/ajg.2010.171","DOI":"10.1038\/ajg.2010.171"},{"key":"10.32074\/1591-951X-164_ref54","doi-asserted-by":"crossref","unstructured":"Duits LC, Phoa KN, Curvers WL, et al. Barrett\u2019s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut 2015;64:700-6. https:\/\/doi.org\/10.1136\/gutjnl-2014-307278","DOI":"10.1136\/gutjnl-2014-307278"},{"key":"10.32074\/1591-951X-164_ref55","doi-asserted-by":"crossref","unstructured":"Horvath B, Singh P, Xie H, et al. Risk for esophageal neoplasia in Barrett\u2019s esophagus patients with mucosal changes indefinite for dysplasia. J Gastroenterol Hepatol 2015;30:262-7. https:\/\/doi.org\/10.1111\/jgh.12696","DOI":"10.1111\/jgh.12696"},{"key":"10.32074\/1591-951X-164_ref56","doi-asserted-by":"crossref","unstructured":"van der Wel MJ, Coleman HG, Bergman JJGHM, et al. Histopathologist features predictive of diagnostic concordance at expert level among a large international sample of pathologists diagnosing Barrett\u2019s dysplasia using digital pathology. Gut 2020;69:811-22. https:\/\/doi.org\/10.1136\/gutjnl-2019-318985","DOI":"10.1136\/gutjnl-2019-318985"},{"key":"10.32074\/1591-951X-164_ref57","doi-asserted-by":"crossref","unstructured":"van der Wel MJ, Duits LC, Pouw RE, et al. Improved diagnostic stratification of digitized Barrett\u2019s oesophagus biopsies by p53 immunohistochemical staining. Histopathology 2018;72:1015-23. https:\/\/doi.org\/10.1111\/his.13462","DOI":"10.1111\/his.13462"},{"key":"10.32074\/1591-951X-164_ref58","doi-asserted-by":"crossref","unstructured":"Tokuyama M, Geisler D, Deitrick C, et al. Use of p53 immunohistochemistry in conjunction with routine histology improves risk stratification of patients with Barrett\u2019s oesophagus during routine clinical care. Histopathology 2020 Online ahead of print. https:\/\/doi.org\/10.1111\/his.14143","DOI":"10.1111\/his.14143"},{"key":"10.32074\/1591-951X-164_ref59","doi-asserted-by":"crossref","unstructured":"Brown IS, Whiteman DC, Lauwers GY. Foveolar type dysplasia in Barrett esophagus.. Mod Pathol 2010;23:834-43. https:\/\/doi.org\/10.1038\/modpathol.2010.59","DOI":"10.1038\/modpathol.2010.59"},{"key":"10.32074\/1591-951X-164_ref60","doi-asserted-by":"crossref","unstructured":"Khor TS, Alfaro EE, Ooi EM, et al. Divergent expression of MUC5AC, MUC6, MUC2, CD10, and CDX-2 in dysplasia and intramucosal adenocarcinomas with intestinal and foveolar morphology: is this evidence of distinct gastric and intestinal pathways to carcinogenesis in Barrett Esophagus? Am J Surg Pathol 2012;36:331-42. https:\/\/doi.org\/10.1097\/PAS.0b013e31823d08d6","DOI":"10.1097\/PAS.0b013e31823d08d6"},{"key":"10.32074\/1591-951X-164_ref61","doi-asserted-by":"crossref","unstructured":"Mahajan D, Bennett AE, Liu X, et al. Grading of Gastric Foveolar-Type Dysplasia in Barrett\u2019s Esophagus. Mod Pathol 2010;23:1-11. https:\/\/doi.org\/10.1038\/modpathol.2009.147","DOI":"10.1038\/modpathol.2009.147"},{"key":"10.32074\/1591-951X-164_ref62","doi-asserted-by":"crossref","unstructured":"Edgren G, Adami HO, Weiderpass E, et al. A global assessment of the oesophageal adenocarcinoma epidemic. Gut 2013;62:1406-14. https:\/\/doi.org\/10.1136\/gutjnl-2012-302412","DOI":"10.1136\/gutjnl-2012-302412"},{"key":"10.32074\/1591-951X-164_ref63","doi-asserted-by":"crossref","unstructured":"Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013;119:1149-58. https:\/\/doi.org\/10.1002\/cncr.27834.","DOI":"10.1002\/cncr.27834"},{"key":"10.32074\/1591-951X-164_ref64","doi-asserted-by":"crossref","unstructured":"Orosey M, Amin M, Cappell MS. A 14-Year Study of 398 Esophageal Adenocarcinomas diagnosed among 156,256 EGDS performed at two large hospitals: an inlet patch is proposed as a significant risk factor for proximal esophageal adenocarcinoma. Dig Dis Sci 2018;63:452-65. https:\/\/doi.org\/10.1007\/s10620-017-4878-2","DOI":"10.1007\/s10620-017-4878-2"},{"key":"10.32074\/1591-951X-164_ref65","unstructured":"Siewert JR, Stein HJ. Carcinoma of the cardia: carcinoma of the gastroesophageal junction - classification, pathology and extent of resection. Dis Esophagus 1996;9:173-82"},{"key":"10.32074\/1591-951X-164_ref66","doi-asserted-by":"crossref","unstructured":"Liu K, Feng F, Chen XZ, et al. Comparison between gastric and esophageal classification system among adenocarcinomas of esophagogastric junction according to AJCC 8th edition: a retrospective observational study from two high-volume institutions in China. Gastric Cancer 2019;22:506-17. https:\/\/doi.org\/10.1007\/s10120-018-0890-2","DOI":"10.1007\/s10120-018-0890-2"},{"key":"10.32074\/1591-951X-164_ref67","doi-asserted-by":"crossref","unstructured":"Bleaney CW, Barrow M, Hayes S, et al. The relevance and implications of signet-ring cell adenocarcinoma of the oesophagus. J Clin Pathol 2018;71:201-6. https:\/\/doi.org\/10.1136\/jclinpath-2017-204863","DOI":"10.1136\/jclinpath-2017-204863"},{"key":"10.32074\/1591-951X-164_ref68","doi-asserted-by":"crossref","unstructured":"Wu J, Pan YM, Wang TT, et al. Endotherapy versus surgery for early neoplasia in Barrett\u2019s esophagus: a meta-analysis. Gastrointest Endosc 2014;79:233-41.e2. https:\/\/doi.org\/10.1016\/j.gie.2013.08.005","DOI":"10.1016\/j.gie.2013.08.005"},{"key":"10.32074\/1591-951X-164_ref69","doi-asserted-by":"crossref","unstructured":"Sharma P, Shaheen NJ, Katzka D, et al. AGA clinical practice update on endoscopic treatment of Barrett\u2019s esophagus with dysplasia and\/or early cancer: expert review. Gastroenterology 2020;158:760-9. https:\/\/doi.org\/10.1053\/j.gastro.2019.09.051","DOI":"10.1053\/j.gastro.2019.09.051"},{"key":"10.32074\/1591-951X-164_ref70","doi-asserted-by":"crossref","unstructured":"Bollschweiler E, Baldus SE, Schroder W, et al. High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. Endoscopy 2006;38:149-56. https:\/\/doi.org\/10.1055\/s-2006-924993","DOI":"10.1055\/s-2006-924993"},{"key":"10.32074\/1591-951X-164_ref71","doi-asserted-by":"crossref","unstructured":"Manner H, May A, Pech O, et al. Early Barrett\u2019s carcinoma with \u201clow-risk\u201d submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol 2008,103:2589-97. https:\/\/doi.org\/10.1111\/j.1572-0241.2008.02083.x","DOI":"10.1111\/j.1572-0241.2008.02083.x"},{"key":"10.32074\/1591-951X-164_ref72","doi-asserted-by":"crossref","unstructured":"Abraham SC, Krasinskas AM, Correa AM, et al. Duplication of the muscularis mucosae in Barrett esophagus: an under-recognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol 2007;31:1719-25. https:\/\/doi.org\/10.1097\/PAS.0b013e318093e3bf.","DOI":"10.1097\/PAS.0b013e318093e3bf"},{"key":"10.32074\/1591-951X-164_ref73","doi-asserted-by":"crossref","unstructured":"Hornick JL, Farraye FA, Odze RD. Prevalence and significance of prominent mucin pools in the esophagus post neoadjuvant chemoradiotherapy for Barrett\u2019s-associated adenocarcinoma. Am J Surg Pathol 2006;30:28-35. https:\/\/doi.org\/10.1097\/01.pas.0000174011.29816.fa","DOI":"10.1097\/01.pas.0000174011.29816.fa"},{"key":"10.32074\/1591-951X-164_ref74","doi-asserted-by":"crossref","unstructured":"Klevebro F, Tsekrekos A, Low D, et al. Relevant issues in tumor regression grading of histopathological response to neoadjuvant treatment in adenocarcinomas of the esophagus and gastroesophageal junction. Dis Esophagus 2020;33:doaa005. https:\/\/doi.org\/10.1093\/dote\/doaa005","DOI":"10.1093\/dote\/doaa005"},{"key":"10.32074\/1591-951X-164_ref75","doi-asserted-by":"crossref","unstructured":"Mandard, AM, Dalibard, F, Mandard, al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73:2680-6. https:\/\/doi.org\/10.1002\/1097-0142(19940601)73:11<2680::aid-cncr2820731105> 3.0.co;2-c.","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C"},{"key":"10.32074\/1591-951X-164_ref76","doi-asserted-by":"crossref","unstructured":"Japanese Society for Esophageal Diseases. Guidelines for clinical and pathologic studies on carcinoma of the esophagus, ninth edition: preface, general principles, part I. Esophagus 2004;1:61-88.","DOI":"10.1007\/s10388-004-0018-0"},{"key":"10.32074\/1591-951X-164_ref77","doi-asserted-by":"crossref","unstructured":"Chirieac LR, Swisher SG, Ajani JA, et al. Post-therapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005;103:1347-55. https:\/\/doi.org\/10.1002\/cncr.20916","DOI":"10.1002\/cncr.20916"},{"key":"10.32074\/1591-951X-164_ref78","doi-asserted-by":"crossref","unstructured":"Swisher SG, Hofstetter W, Wu TT, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response following preoperative chemoradiation. Ann Surg 2005;241:810-20. https:\/\/doi.org\/10.1097\/01.sla.0000161983.82345.85","DOI":"10.1097\/01.sla.0000161983.82345.85"},{"key":"10.32074\/1591-951X-164_ref79","doi-asserted-by":"crossref","unstructured":"Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005;242:684-92. https:\/\/doi.org\/10.1097\/01.sla.0000186170.38348.7b","DOI":"10.1097\/01.sla.0000186170.38348.7b"},{"key":"10.32074\/1591-951X-164_ref80","doi-asserted-by":"crossref","unstructured":"Sawada G, Moon J, Saito A, et al., A case of adenoid cystic carcinoma of the esophagus. Surg Case Rep, 2015;1:119. https:\/\/doi.org\/10.1186\/s40792-015-0122-5","DOI":"10.1186\/s40792-015-0122-5"},{"key":"10.32074\/1591-951X-164_ref81","doi-asserted-by":"crossref","unstructured":"Chen SB, Weng HR, Wang G, et al. Primary adenosquamous carcinoma of the esophagus. World J Gastroenterol 2013;19:8382-90. https:\/\/doi.org\/10.3748\/wjg.v19.i45.8382","DOI":"10.3748\/wjg.v19.i45.8382"},{"key":"10.32074\/1591-951X-164_ref82","doi-asserted-by":"crossref","unstructured":"Evans M, Liu Y, Chen C, et al. Adenosquamous carcinoma of the esophagus: An NCDB-Based Investigation on comparative features and overall survival in a rare tumor. Oncology 2017;93:336-42. https:\/\/doi.org\/10.1159\/000466699","DOI":"10.1159\/000466699"},{"key":"10.32074\/1591-951X-164_ref83","doi-asserted-by":"crossref","unstructured":"Chen S, Chen Y, Yang J, et al. Primary Mucoepidermoid Carcinoma of the Esophagus J Thorac Oncol 2011;6:1426-31. https:\/\/doi.org\/10.1097\/JTO.0b013e31821cfb96","DOI":"10.1097\/JTO.0b013e31821cfb96"},{"key":"10.32074\/1591-951X-164_ref84","doi-asserted-by":"crossref","unstructured":"Singhi AD, Seethala RR, Nason K, et al. Undifferentiated Carcinoma of the Esophagus: A Clinicopathological Study of 16 Cases. Hum Path 2015;46:366-75. https:\/\/doi.org\/10.1016\/j.humpath.2014.11.021","DOI":"10.1016\/j.humpath.2014.11.021"},{"key":"10.32074\/1591-951X-164_ref85","doi-asserted-by":"crossref","unstructured":"Babar L, Kosovec JE, Jahangiri V, et al. Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinoma. Oncotarget 2019;10:4546-55. https:\/\/doi.org\/10.18632\/oncotarget.27052","DOI":"10.18632\/oncotarget.27052"},{"key":"10.32074\/1591-951X-164_ref86","doi-asserted-by":"crossref","unstructured":"Jacobsen F, Hohsar J, Gebauer F, et al. Loss of p16 and high Ki67 labeling index is associated with poor outcome in esophageal carcinoma. Oncotarget 2020;11:1007-16. https:\/\/doi.org\/10.18632\/oncotarget.27507","DOI":"10.18632\/oncotarget.27507"},{"key":"10.32074\/1591-951X-164_ref87","doi-asserted-by":"crossref","unstructured":"Fassan M, Mastracci L, Grillo F, et al. Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology 2012;61:769-76. https:\/\/doi.org\/10.1111\/j.1365-2559.2012.04272.x","DOI":"10.1111\/j.1365-2559.2012.04272.x"},{"key":"10.32074\/1591-951X-164_ref88","doi-asserted-by":"crossref","unstructured":"R\u00fcschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299-307. https:\/\/doi.org\/10.1007\/s00428-010-0952-2","DOI":"10.1007\/s00428-010-0952-2"},{"key":"10.32074\/1591-951X-164_ref89","doi-asserted-by":"crossref","unstructured":"Grillo F, Fassan M, Sarocchi F, et al. HER2 heterogeneity in gastric\/gastroesophageal cancers: from benchside to practice. World J Gastroenterol 2016;22:5879-87. https:\/\/doi.org\/10.3748\/wjg.v22.i26.5879","DOI":"10.3748\/wjg.v22.i26.5879"},{"key":"10.32074\/1591-951X-164_ref90","doi-asserted-by":"crossref","unstructured":"Grillo F, Fassan M, Ceccaroli C, et al. The reliability of endoscopic biopsies in assessing HER2 status in gastric and gastroesophageal junction cancer: a study comparing biopsies with surgical samples. Transl Oncol 2013;6:10-6. https:\/\/doi.org\/10.1593\/tlo.12334","DOI":"10.1593\/tlo.12334"},{"key":"10.32074\/1591-951X-164_ref91","doi-asserted-by":"crossref","unstructured":"Gullo I, Grillo F, Molinaro L, et al. Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer. Endosc Int Open 2015;3:E165-70. https:\/\/doi.org\/10.1055\/s-0034-1391359","DOI":"10.1055\/s-0034-1391359"},{"key":"10.32074\/1591-951X-164_ref92","doi-asserted-by":"crossref","unstructured":"Farris AB 3rd, Demicco EG, Le LP, et al. Clinicopathologic and molecular profiles of microsatellite unstable Barrett Esophagus-associated adenocarcinoma. Am J Surg Pathol 2011;35:647-55. https:\/\/doi.org\/10.1097\/PAS.0b013e31820f18a2","DOI":"10.1097\/PAS.0b013e31820f18a2"},{"key":"10.32074\/1591-951X-164_ref93","doi-asserted-by":"crossref","unstructured":"van Velzen MJM, Derks S, van Grieken NCT, et al. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. Cancer Treat Rev 2020;86:102024. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102024","DOI":"10.1016\/j.ctrv.2020.102024"},{"key":"10.32074\/1591-951X-164_ref94","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature 2017;541:169-75. https:\/\/doi.org\/10.1038\/nature20805","DOI":"10.1038\/nature20805"},{"key":"10.32074\/1591-951X-164_ref95","doi-asserted-by":"crossref","unstructured":"Secrier M, Li X, de Silva N, et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet 2016;48:1131-41. https:\/\/doi.org\/10.1038\/ng.3659","DOI":"10.1038\/ng.3659"},{"key":"10.32074\/1591-951X-164_ref96","doi-asserted-by":"crossref","unstructured":"Hassanabad AF, Chehade R, Breadner D, et al. Esophageal carcinoma: towards targeted therapies. Cell Oncol (Dordr) 2020;43:195-209. https:\/\/doi.org\/10.1007\/s13402-019-00488-2","DOI":"10.1007\/s13402-019-00488-2"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:25:06Z","timestamp":1730813106000},"score":1,"resource":{"primary":{"URL":"https:\/\/old.pathologica.it\/article\/view\/164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":96,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-164","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]},"article-number":"4"}}